Post Reply
621-640 of 1197
this onequite tricky
starting..
I meant other medtech companies have risen so much and trendlines still at this price...
Wat does this mean
Maller ( Date: 14-Jul-2020 21:39) Posted:
|
Haven' t move yet, similar stocks and others already so high,,,dyodd
time to move next!!!!
TIME to breakout tgt with HYPHENS IX.......
Can see someone blocking trendlines? Why? However, dont go against mkt force, it will rise as other medical related stocks already rose so high. Dyodd
Yup and amidst euphoria elsewhere, this will be a good one to ride the waves
When others riae enough, this one will follow? Dyodd
Share price cannot make it. Why so lousy?
Accumulating la
Got sellers attacking
Trendlines Medical Singapore is Trendlines&rsquo third technology start-up incubator, joining Israel-based incubators Trendlines Medical and Trendlines Agtech. Trendlines Medical Singapore was established in 2016 by The Trendlines Group and B. Braun, one of the world&rsquo s leading medical device players.....
Ya, but surprised why haven' t cheong yet? All its peers and medical stocks cheong liao..Could be good opportunity to collect and hold?
Its a diversified medical portfolio with strong SSH. Keep calm amidst rising waves.
Waiting, all other medical stocks cheong to sky liao. The medical related company is waiting ti be triggered. Sooner or later in my view. Dyodd
Timer78 ( Date: 09-Jul-2020 21:37) Posted:
|
NAV is USD 13cts. Dyodd but this is an under valued gem.
Excerpts of AGM for reference:
Regarding our share price, the Board believes that the current market price of Trendlines does not properly
reflect the Company?s value. Since our IPO, our share price has declined while the value of our portfolio,
taken as the sum of the appraised value and exit proceeds received to date, has increased by 32.7%. In
comparison to peer companies, Trendlines? share price trades at a large discount. The CEOs and
management continue to work hard to increase value for the Company and its shareholders.
The private placement in 2019 was completed at 10.5 Singapore cents per share, a 34.6% premium over
the last traded price of the full market day prior to the date of the subscription agreement. The rights
offering occurred at an issue price representing a 19.3% premium to the last traded price prior to the
announcement of the rights offering.
It should further be noted relative to these issuances that:
a. Raising capital at significant premiums to the current trading price is unusual and served to call
positive attention to our share price which, in turn, was followed by an increase in market price and
increased volumes.
b. The private placement and rights offering resulted in Librae holding 23.03% of the Company. We
believe that Librae?s significant investment demonstrates their belief in the Company and its
prospects.
c. With the rights offering following the private placement, the Board provided an opportunity for
shareholders to invest at the same terms as Librae
Excerpts of AGM for reference:
Regarding our share price, the Board believes that the current market price of Trendlines does not properly
reflect the Company?s value. Since our IPO, our share price has declined while the value of our portfolio,
taken as the sum of the appraised value and exit proceeds received to date, has increased by 32.7%. In
comparison to peer companies, Trendlines? share price trades at a large discount. The CEOs and
management continue to work hard to increase value for the Company and its shareholders.
The private placement in 2019 was completed at 10.5 Singapore cents per share, a 34.6% premium over
the last traded price of the full market day prior to the date of the subscription agreement. The rights
offering occurred at an issue price representing a 19.3% premium to the last traded price prior to the
announcement of the rights offering.
It should further be noted relative to these issuances that:
a. Raising capital at significant premiums to the current trading price is unusual and served to call
positive attention to our share price which, in turn, was followed by an increase in market price and
increased volumes.
b. The private placement and rights offering resulted in Librae holding 23.03% of the Company. We
believe that Librae?s significant investment demonstrates their belief in the Company and its
prospects.
c. With the rights offering following the private placement, the Board provided an opportunity for
shareholders to invest at the same terms as Librae
Trendlines is an innovation commercialization company that invents, discovers, invests
in, and incubates innovation-based medical and agricultural technologies to fulfill its
mission to improve the human condition. As intensely hands-on investors, Trendlines is
involved in all aspects of its portfolio companies from technology development to
business building
in, and incubates innovation-based medical and agricultural technologies to fulfill its
mission to improve the human condition. As intensely hands-on investors, Trendlines is
involved in all aspects of its portfolio companies from technology development to
business building
Others medical related stocks past few weeks cheong so much, this one still lags. Maybe wait until bbs interests come. Can go up to 20 cents?? Dyodd